2022.L06.B – Low Dose Naltrexone

Low Dose Naltrexone (LDN) for Spike-Induced Disease: Why and How!

Lecture abstract:

According to the U.S. General Accountability Office, as many as 23 million Americans suffer from long COVID. Fortunately, we have a new weapon in our arsenal: low-dose naltrexone (LDN), a medication discovered in the 1980s as a potential treatment for autoimmune disease and fibromyalgia. By 2016, this unique medication had over 300,000 users and more than 60 research studies touting its benefits.

I will discuss several different mechanisms behind spike protein-induced disease and how LDN has become a key treatment option. LDN possesses multiple mechanisms of action, allowing it to help with dysfunctional cytokine response, neuroinflammation, chronic pain, histamine intolerance, and post-viral reactivation.

About the Speaker

A founding member of the FLCCC Alliance, Keith Berkowitz’s expertise combines both traditional and complementary medicine. Before starting The Center for Balanced Health, a private practice in Internal Medicine located in New York City, he was the Medical Director of The Atkins Center for Complementary Medicine and was a member of the teaching faculty at North Shore University Hospital.

Dr. Berkowitz is the co-author of “The Stubborn Fat Fix”, “The Complete Idiot’s Guide to Flour Free Eating”, and “The Princeton Review: Medical School Companion”.

He received his Bachelor of Arts from Brandeis University, attended medical school at New York Medical College in Valhalla, New York, received an MBA from Columbia Business School, and is a member of the Beta Gamma Sigma Honor Society. Dr. Berkowitz completed his residency in Internal Medicine at North Shore University Hospital and Memorial Sloan Kettering Cancer Center.

Dr. Keith Berkowitz thumbnail image 200x200

MD, MBA
Founder and Medical Director
The Center for Balanced Health

Lecture Downloads

Share this Lesson
We use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so. Read our Privacy Policy ACCEPT